Cost remains a major factor for employers as the popular drug for weight loss represented 11.4% of annual claims for corporations in 2025.
An article from
Dive Brief
Cost remains a major factor for employers as the popular drug for weight loss represented 11.4% of annual claims for corporations in 2025.
Published July 16, 2026
The injectable weight loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024, in Chicago, Ill. The U.S. adult obesity rate has fallen from a record high in 2022, a “meaningful decline" that inversely tracks with increased usage of GLP-1s, Gallup found.
Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34%…
Companies have “tremendous concern” about the financial viability of these medications, the president and CEO of the Business…
GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that…
Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss…
15% of Americans have ever taken the drugs, up from 6% in 2024.
About 43% of employers covered the drugs for weight-loss in 2025, and estimates for 2026 are about the same
